Hepatitis C is an infectious disease of the liver that can be mild to severe. Infection in some people lasts a few weeks while for others a lifetime, leading to serious illness that severely damages the liver.

According to Justin Bailey, M.D., Ph.D., assistant professor of medicine in the Division of Infectious Diseases in the Johns Hopkins University School of Medicine, there is no individual antibody that can attack all kinds of hepatitis C virus strains. This may be the reason for which only one-third of people clear the virus from their body, while other people suffer from chronic disease.

Bailey and his colleague, Stuart C. Ray, M.D., professor of medicine in the Division of Infectious Diseases in the Johns Hopkins University School of Medicine, along with other scientists studied 18 antibodies that attack the hepatitis C virus and compared them to 19 strains of virus that are responsible for 94 percent of hepatitis C virus genetic variability. All of the strains were from the most common genetic group, known as genotype 1.

The scientists were able to identify three main groups of antibodies, based on their tendency to attack the same viral strain subsets. But what was common about these groups?

It turned out to have something to do with the viral envelopes that make up the viruses’ outer covering. Depending on how the covering was composed by proteins, the virus would be rendered susceptible to different antibody groups.

The researchers then tested blood plasma samples from 18 people who were chronically infected with hepatitis C. The viral variations leading to antibody resistance in hepatitis C studied in a dish in the lab predicted antibody resistance in the plasma of these infected individuals. The lab studies were then confirmed by actual infected patients.

According to Bailey, this means that a vaccine needs to be ideally tailored to account for all of the genetic diversity that occurs in the virus. Antibody combinations will likely be needed in order to develop a vaccine. Bailey remarked, “We can now start to identify antibodies from different clusters that are likely to be complementary to each other in their neutralizing ability, rather than using antibodies from just a single cluster.”

Disclaimer:

Hepatitis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more